Depression
Conditions
Brief summary
Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment. The aim of this study is to investigate the relation between the cognitive changes and the remission of depressive symptoms in patients with recurrent depression (Stage 2 of Thase and Rush classification). To explore the dynamics of cognitive dimension associated to clinical and functional remission, the investigators will observe neurocognitive functioning before and after introducing a new antidepressive therapy.
Interventions
BEHAVIORALRecurrent depression
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients will be aged from 40 to 70, with a major depressive episode diagnosis with a 2 stage degree of resistance.
Exclusion criteria
* Patients with major depressive episode during more of 12 months * Alzheimer dementia or related disease (CIM 10) * Score Hamilton Depression Rating Scale (HDRS) \< 18
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinic assessments: Score BDI - II | Change from the baseline score BDI-II at 12 months after introducing the new therapy | The investigators will conduct clinical assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be clinically assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy. |
| Functional assessments : Score Sheehan Disability Scale (SDS) | Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy | The investigators will conduct functional assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be functional assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy. |
| Neuropsychologic assessments: M.M.S.E. (Mini Mental Score Evaluation) | Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy | The investigators will conduct neuropsychologic assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; A complete assessment will be done 6 months and 12 months after introducing the new therapy. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORNelly Darmon
CHU of Nice
Outcome results
None listed